Arrowhead Pharmaceuticals, Inc. ARWR
43.11 USD +0.12 (+0.28%)
Regular-session close
43.11 0.00 0.00%
After hours · Nov 18, 4:54 PM ET
42.46 Day range 43.99
37.06 52-week range 95.49
- YTD
- -35.07%
- 1 year
- +6.52%
News
seekingalpha.com Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Jefferies Global Healthcare Conference 2026 Transcript Arrowhead Pharmaceuticals, Inc. ( ARWR ) Jefferies Global Healthcare Conference 2026 November 18, 2026 6:00 AM EST Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference…
businesswire.com Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the…benzinga.com Citigroup Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $105 Citigroup analyst Eric Joseph maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $108 to $105.
defenseworld.net 94,000 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR Bought by ACT Capital Partners L.P. ACT Capital Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) in the third quarter, according to its most recent 13F filing with the Securities and…benzinga.com RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.
benzinga.com Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96 Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.
seekingalpha.com Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript
marketbeat.com Arrowhead Pharmaceuticals Q4 Earnings Call Highlights Arrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing…benzinga.com Arrowhead Pharma Q4 EPS $(3.01) Misses $(1.61) Estimate, Sales $37.794M Miss $55.838M Estimate Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(3.01) per share which missed the analyst consensus estimate of $(1.61) by 86.96 percent. This is a 1572.22 percent decrease over losses…
businesswire.com Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting…
benzinga.com Cisco Systems, Applied Materials On Deck Thursday As AI Demand Faces Test Cisco Systems and Applied Materials headline Thursday’s reports, with investors looking for evidence that AI infrastructure demand can keep supporting semiconductor and networking growth. Brookfield,…
businesswire.com Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026…
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.benzinga.com Reported Saturday, Arrowhead Presents Plozasiran Data At AHA 2026 Showing 78% Lower Acute Pancreatitis Event Rate Versus Placebo And Sustained Triglyceride Reductions, Plus ARO-DIMER-PA Lowering LDL Cholesterol And Triglycerides Pooled SHASTA-3 and SHASTA-4 analysis showed plozasiran reduced acute pancreatitis event rates by 78% overall and 91% in sHTG patients with a recent history of acute pancreatitis versus…
gurufocus.com Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at
businesswire.com Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the…benzinga.com Arrowhead Refinances Debt, Cuts Borrowing Costs And Boosts Financial Flexibility With New $400M Sixth Street Loan - Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount- New $400 million term loan priced at SOFR plus 5.50%- Debt has no scheduled…
businesswire.com Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing…benzinga.com Arrowhead Pharma To Present Three-Year Data From PALISADE Study And Open-Label Extension At American Heart Association Scientific Sessions 2026 – Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking…
businesswire.com Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026 PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in…benzinga.com Arrowhead Pharmaceuticals’ REDEMPLO Receives UK Marketing Authorization For Familial Chylomicronaemia Syndrome; NICE Recommends NHS Funding In England And Wales For Eligible Adults With Genetically Confirmed FCS The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation for REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglyceride levels in adult patients…
businesswire.com Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial…
benzinga.com Top 3 Health Care Stocks That Could Blast Off In October Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
defenseworld.net Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) DBV Technologies (NASDAQ: DBVT - Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ: ARWR - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the…
seekingalpha.com Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. ARWR plans to expand its…
seekingalpha.com Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
marketbeat.com Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study Arrowhead Pharmaceuticals NASDAQ: ARWR presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central…
businesswire.com Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA…
businesswire.com Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in…
defenseworld.net Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $75.86 and traded…
seekingalpha.com Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and…
